Skip to Content

Alfonso Quintas-Cardama

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1994 Universidad de Santiago de Compostela, School of Medicine, Santiago de Compostela, La Coruña, Spain, MD, Medicine and Surgery

Postgraduate Training

7/2006-6/2009 Clinical Fellowship, Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Robert Wolff, M.D.
7/2005-6/2006 Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, Jorge E. Cortes, M.D.
7/2002-6/2005 Clinical Residency, Internal Medicine, Albert Einstein College of Medicine, Bronx, NY, Steven C. Martin, M.D.
4/1997-4/2000 Clinical Fellowship, Hematology, University of Santiago Clinical Hospital, Santiago, Spain
4/1996-3/1997 Clinical Internship, Internal Medicine, University of Santiago Clinical Hospital, Santiago, Spain

Selected Publications

Peer-Reviewed Original Research Articles
1. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: implications for the treatment of myeloproliferative neoplasms. Blood 115(15):3109-17, 4/15/2010. e-Pub 2/3/2010. PMID: 20130243.
2. Quintás-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 27(28):4760-6, 10/1/2009. e-Pub 8/31/2009. PMID: 19720904.
3. Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S. Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera. J Clin Oncol, 10/13/2009. e-Pub 10/13/2009. PMID: 19826111.
4. Quintás-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond--exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 6(9):535-43, 9/2009. e-Pub 8/4/2009. PMID: 19652654.
5. Quintás-Cardama A, Cortes JE, O'Brien S, Ravandi F, Borthakur G, Liu D, Bleickardt E, Chen TT, Kantarjian HM. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 115(13):2912-21, 7/1/2009. PMID: 19402171.
6. Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 114(2):261-3, 7/9/2009. e-Pub 5/4/2009. PMID: 19414863.
7. Quintás-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S, Cortes J. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113(25):6315-21, 6/18/2009. e-Pub 4/15/2009. PMID: 19369233.
8. Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113(8):1619-30, 2/19/2009. e-Pub 9/30/2008. PMID: 18827185.

Last updated: 8/26/2010